ReviewEndocrine2022
Aggressive variants of follicular cell-derived thyroid carcinoma: an overview.
Review in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Construction and validation of a nomogram for predicting cervical lymph node metastasis in diffuse sclerosing variant of papillary thyroid carcinoma.Langenbeck's archives of surgery · 2023Trial
- Development of a clinically applicable prediction tool for lymph node metastasis in papillary thyroid carcinoma using lasso-logistic regression.BMC cancer · 2026Article
- The shifting paradigm of programmed cell death ligand 1 (PD-L1) in anaplastic thyroid carcinoma: from pathology to clinical practice.Virchows Archiv : an international journal of pathology · 2026Review
- Epidemiology and prognostic factors of Hürthle-oncocytic cell carcinoma of the thyroid.Discover oncology · 2026Article
- Clinicopathological Significance of Ultrasound Risk Features and the Taller-Than-Wide Sign for Tumor Advancement in Differentiated Thyroid Cancer: A Single-Center Analysis.Cancer management and research · 2026Article
- Prognostic Significance of Solid Subtype of Papillary Thyroid Carcinoma: Analysis of 63 Patients.Head & neck · 2026Article
- ITGA3-MET interaction promotes papillary thyroid cancer progression via ERK and PI3K/AKT pathways.Annals of medicine · 2025Article
- The combined detection of aspiration biopsy, computed tomography and BRAFV600E gene has high diagnostic value for papillary thyroid carcinoma.Archives of endocrinology and metabolism · 2025Article
- Evaluation of predictive factors for lymph node metastasis in thyroid microcarcinoma: a two-year experience from two high-volume centers.Updates in surgery · 2025Article
- BRAF V600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression.Endocrine connections · 2025Article
- Associations between pathological features and radioactive iodine-refractory recurrent papillary thyroid carcinoma: with mutation analysis using recurrent samples.BMC endocrine disorders · 2025Article
- Aggressive variants of papillary thyroid carcinoma: characteristics, influencing factors, and effectiveness of radioiodine therapy.Journal of endocrinological investigation · 2025Article
- Aggressive Types of Malignant Thyroid Neoplasms.Journal of clinical medicine · 2024Review
- Histologic Evaluation of Thyroid Nodules Treated with Thermal Ablation: An Institutional Experience.International journal of molecular sciences · 2024Article
- A Comprehensive Review and Insights into the New Entity of Differentiated High-Grade Thyroid Carcinoma.Current oncology (Toronto, Ont.) · 2024Review
- Papillary thyroid carcinoma: ≤ 10 mm does not always mean pN0. A multicentric real-world study.Updates in surgery · 2024Article
- Correlation analysis between BRAFHeliyon · 2024Article
- Article
- miR-331-5p Affects Motility of Thyroid Cancer Cell Lines and Regulates BID Expression.Biomedicines · 2024Article
- Are Higher Body Mass Index and Worse Metabolic Parameters Associated with More Aggressive Differentiated Thyroid Cancer? A Retrospective Cohort Study.Healthcare (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe incidence of thyroid carcinoma has increased globally in the past years. Papillary thyroid carcinoma (PTC) is the most frequent neoplasm of the thyroid gland comprehending the 90% of the thyroid carcinoma and has an indolent clinical behaviour. However, some variants of follicular cell-derived thyroid carcinoma, including variants of classic of PTC, have been identified that show a more aggressive biological behaviour. An accurate diagnosis of these entities is crucial for planning a more aggressive treatment and improving patients' prognosis of patients. The aim of this review is to present the main clinical, histological, and molecular features of aggressive variants of follicular cell-derived thyroid carcinoma, and to provide useful histological parameters for determining the most suitable therapeutic strategy for patients affected by these forms.
resultsVariants of classic PTC such as the diffuse sclerosing variant (DSV), the tall cell variant (TCV), the columnar cell variant (CCV), the solid/trabecular variant (STV) and the hobnail variant (HV), and other variants of follicular cell-derived thyroid carcinoma, such as poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC), are associated with aggressive behaviour.
conclusionsThe correct identification and diagnosis of aggressive variants of follicular cell-derived thyroid carcinoma is important, as they allow the clinician to adopt the most refined therapeutic strategies in order to the survival of the patients.
Indexed as
Identifiers
35864338What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.